Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 12;13(20):1688.
doi: 10.3390/cells13201688.

The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases

Edit Posta  1 , Istvan Fekete  2 , Istvan Varkonyi  1 , Eva Zold  3 , Zsolt Barta  1
Affiliations
Review

The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases

Edit Posta et al. Cells. .

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that sense lipophilic molecules and act as transcription factors to regulate target genes. PPARs have been implicated in the regulation of innate immunity, glucose and lipid metabolism, cell proliferation, wound healing, and fibrotic processes. Some synthetic PPAR ligands are promising molecules for the treatment of inflammatory and fibrotic processes in immune-mediated intestinal diseases. Some of these are currently undergoing or have previously undergone clinical trials. Dietary PPAR ligands and changes in microbiota composition could modulate PPARs' activation to reduce inflammatory responses in these immune-mediated diseases, based on animal models and clinical trials. This narrative review aims to summarize the role of PPARs in immune-mediated bowel diseases and their potential therapeutic use.

Keywords: Crohn’s disease; PPAR; allergic diseases; celiac disease; eosinophilic gastrointestinal disorders; inflammation; microbiome; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

References

    1. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–650. doi: 10.1038/347645a0. - DOI - PubMed
    1. Bunger M., van den Bosch H.M., van der Meijde J., Kersten S., Hooiveld G.J., Muller M. Genome-wide analysis of PPARalpha activation in murine small intestine. Physiol. Genom. 2007;30:192–204. doi: 10.1152/physiolgenomics.00198.2006. - DOI - PubMed
    1. Guo Y.X., Wang B.Y., Gao H., Hua R.X., Gao L., He C.W., Wang Y., Xu J.D. Peroxisome Proliferator-Activated Receptor-alpha: A Pivotal Regulator of the Gastrointestinal Tract. Front. Mol. Biosci. 2022;9:864039. doi: 10.3389/fmolb.2022.864039. - DOI - PMC - PubMed
    1. Daoudi M., Hennuyer N., Borland M.G., Touche V., Duhem C., Gross B., Caiazzo R., Kerr-Conte J., Pattou F., Peters J.M., et al. PPARbeta/delta activation induces enteroendocrine L cell GLP-1 production. Gastroenterology. 2011;140:1564–1574. doi: 10.1053/j.gastro.2011.01.045. - DOI - PubMed
    1. Doktorova M., Zwarts I., Zutphen T.V., Dijk T.H.V., Bloks V.W., Harkema L., Bruin A.D., Downes M., Evans R.M., Verkade H.J., et al. Intestinal PPARdelta protects against diet-induced obesity, insulin resistance and dyslipidemia. Sci. Rep. 2017;7:846. doi: 10.1038/s41598-017-00889-z. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources